Abstract | OBJECTIVE: DESIGN AND SETTING: A prospective clinical study conducted in an intensive care unit. PATIENTS: Nine patients (four men, five women, mean age 71 +/- 3 years) with confirmed or suspected bacterial infection and with refractory septic shock defined as a mean arterial pressure < or = 70 mmHg despite norepinephrine infusion > or = 0.2 microg/kg per minute. INTERVENTIONS: MEASUREMENTS AND RESULTS: The urinary excretion of NO metabolites decreased with median 90% (range 75-95%) from baseline to 6 h after MB administration. The first 24 h creatinine clearance improved by 51% (18-173%) after MB treatment but was still strongly impaired. During the first 6 h after the start of MB treatment both the urinary excretion of cytosolic glutathione S-transferase A1-1 and P1-1, markers for proximal and distal tubule damage, respectively, decreased by 45% (10-70%) and 70% (40-85) vs. baseline. After termination of the MB infusion the NO metabolites and markers of tubular injury returned to pretreatment levels. CONCLUSIONS: In septic patients with refractory shock short-term infusion of MB is associated with a decrease in NO production and an attenuation of the urinary excretion of renal tubular injury markers.
|
Authors | Suzanne Heemskerk, Frank M P van Haren, Norbert A Foudraine, Wilbert H M Peters, Johannes G van der Hoeven, Frans G M Russel, Rosalinde Masereeuw, Peter Pickkers |
Journal | Intensive care medicine
(Intensive Care Med)
Vol. 34
Issue 2
Pg. 350-4
(Feb 2008)
ISSN: 0342-4642 [Print] United States |
PMID | 17926021
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Enzyme Inhibitors
- Nitric Oxide Synthase
- Glutathione Transferase
- Methylene Blue
|
Topics |
- Acute Kidney Injury
(drug therapy, enzymology, etiology)
- Aged
- Analysis of Variance
- Enzyme Inhibitors
(therapeutic use)
- Female
- Glutathione Transferase
(metabolism)
- Humans
- Male
- Methylene Blue
(therapeutic use)
- Nitric Oxide Synthase
(metabolism)
- Prospective Studies
- Shock, Septic
(complications, enzymology)
- Treatment Outcome
|